Comparison of the molecular genetics of c‐erb‐B2 and p53 expression in stomach cancer in Britain and Japan

Background. Differences in the epidemiology and treatment outcome of stomach cancer have led to the suggestion that in Japan, this disease may be biologically less aggressive than that found in the West. The authors compared p53b and c‐erb‐B2 expression, trying to identify genetic differences in Japanese compared with Western stomach cancers.

[1]  S. Hirohashi,et al.  Overexpression of c‐erbB‐2 protein in gastric cancer. Its correlation with long‐term survival of patients , 1993, Cancer.

[2]  G. Thompson,et al.  Adenocarcinoma of the stomach: are we making progress? , 1993, The Lancet.

[3]  S. Hirohashi,et al.  p53 Mutation in gastric cancer: A genetic model for carcinogenesis is common to gastric and colorectal cancer , 1993, International journal of cancer.

[4]  H. Sasano,et al.  Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. , 1993, Human pathology.

[5]  T. Kameya,et al.  An immunohistochemical study of c‐erbb‐2 protein in gastric carcinomas and lymph‐node metastases: Is the c‐erbB‐2 protein really a prognostic indicator? , 1993, International journal of cancer.

[6]  M. Rugge,et al.  Immunohistochemical evidence of p53 overexpression in gastric epithelial dysplasia. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[7]  S. Hirohashi,et al.  High incidence of nuclear accumulation of p53 protein in gastric cancer. , 1992, Japanese journal of clinical oncology.

[8]  A. Tandon,et al.  A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  K. West,et al.  c-erbB-2 oncogene product expression and prognosis in gastric carcinoma. , 1992, Journal of clinical pathology.

[10]  Y. Minamisono,et al.  Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinoma , 1992, Journal of surgical oncology.

[11]  D. Lane,et al.  p53 expression and prognosis in gastric carcinoma , 1992, International journal of cancer.

[12]  S. Hirohashi,et al.  p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. , 1991, Cancer research.

[13]  W. Gullick,et al.  c‐erbB‐2 proto‐oncogene expression and its relationship to survival in gastric carcinoma: An immunohistochemical study on archival material , 1991, International journal of cancer.

[14]  N. Lemoine,et al.  Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. , 1991, British Journal of Cancer.

[15]  Y. Nakamura,et al.  Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. , 1991, Cancer research.

[16]  Takuma Sasaki,et al.  Expression of C‐erbB‐2 oncoprotein in gastric carcinoma. Immunoreactivity for C‐erbB‐2 protein is an independent indicator of poor short‐term prognosis in patients with gastric carcinoma , 1991, Cancer.

[17]  S. Hirohashi,et al.  Detection of frequent p53 gene mutations in primary gastric cancer by cell sorting and polymerase chain reaction single-strand conformation polymorphism analysis. , 1991, Cancer research.

[18]  Teruhiko Yoshida,et al.  K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Ito,et al.  Alterations of oncogenes in metastatic tumours of human gastric carcinomas. , 1990, British Journal of Cancer.

[20]  J. Fielding.  Gastric cancer: Different diseases , 1989, The British journal of surgery.

[21]  Tanaki Kajitani,et al.  The general rules for the gastric cancer study in surgery and pathology , 1981, The Japanese journal of surgery.

[22]  Y. Maehara,et al.  Unregulated emissions from catalyst-equipped cars: EPA overview. , 1975, British Journal of Cancer.

[23]  Carcinoma , 1906, The Hospital.

[24]  A. Thompson,et al.  Correlation between p53 mutations and antibody staining in breast carcinoma. , 1994, The British journal of surgery.